Australian doctors transplant first circulatory death human heart

The St Vincent's Hospital Heart Lung Transplant Unit has carried out the world's first distant procurement of hearts donated after circulatory death (DCD). These hearts were subsequently resuscitated and then successfully transplanted into patients with end-stage heart failure.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

In conclusion, this is the first report to show that pyroptotic cell death occurs in the aging brain and that the inflammasome can be a viable target to decrease the oxidative stress that occurs as a result of aging. Reducing Levels of Protein Manufacture Slows Measures of Aging in Nematodes https://www.fightaging.org/archives/2018/12/reducing-levels-of-protein-manufacture-slows-measures-of-aging-in-nematodes/ Researchers here demonstrate that an antibiotic slows aging in nematode worms, providing evidence for it to work through a reduction in protein synthesis. Beyond a slowing of aging, one of the con...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Heart transplantation is the definitive treatment for end-stage heart failure. A shortage of donor hearts forced transplant programs to accept older donors and longer ischemic times. Previous studies have suggested that the administration of mesenchymal stem cells (MSCs) or their conditioned medium (CM) protects the heart against ischemia/reperfusion injury (IRI). We hypothesized that the preservation of donor hearts with a CM would protect the graft from IRI after prolonged storage in 15-month-old rats and investigated mRNA-changes attributable to CM.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Pre-Clinical Science Source Type: research
We learn from basic physiology  lessons that human body is made up of 60 % water. What about heart ? There is no reason for the heart should behave differently from rest of the body . If my  assumptions are correct when the normal heart weighs 300g  , 180g of which should be  be water. The same thing could be applicable for LV mass( * Reference requested) Is there myocardial congestion in cardiac failure ? Genesis of edema in any tissue depends on local hydrostatic pressures, tissue resistive forces, osmotic balance, and cell membrane permeability. In the myocardium individual contri...
Source: Dr.S.Venkatesan MD - Category: Cardiology Authors: Tags: cardiac failure Cardiac MRI Cardio Nephrology effect of dialysis on myocardial water content lv amss and myocardial edema myocardial edema and ckd chronic kidney failure myocardial interstitial edema myocardial water imaging water logging Source Type: blogs
Pediatric heart transplantation is considered a standard therapy for end-stage heart failure refractory to medical and surgical therapy.1 Since its inception in 1967, heart transplant use has continually increased with expansion to more complex populations.2,3 A recent International Society of Heart and Lung Transplantation (ISHLT) report evaluated post-transplant outcomes among different transplant indications and found that despite ongoing improvement in overall pediatric transplant survival, there remains a persistent survival advantage for dilated cardiomyopathy compared to congenital heart disease (CHD) and re-transplantation.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: Clinical Investigation Source Type: research
ConclusionsVarious biomarkers are associated with the event-free survival in adults with PH. However, risk stratification exclusively based on single or a combination of biomarkers seems not superior to existing risk scores.
Source: American Heart Journal - Category: Cardiology Source Type: research
Despite the numerous innovations in all diagnostic and treatment aspects of congenital heart disease, the management of pulmonary vein stenosis (PVS), primary or postoperative, continues to be perplexing and 1-2 year survival of patients with progressive PVS seems to have stubbornly plateaued at a low range of 50-60%.1-4 Various medical, percutaneous and surgical treatment modalities for PVS have been described. Nonetheless, all those options continue to be associated with inferior outcomes due to residual lesions, recurrent stenosis secondary to disease progression in the same or other pulmonary veins, development of pulm...
Source: Seminars in Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Congenital – Editorial Commentary Source Type: research
Conclusions: Prognosis was poor and comorbidity burden was substantial in the cohort of patients with PF and subcohort with IPF.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Rare ILD/DPLD Source Type: research
Conclusion: Despite the development of treatments, the recent implementation of screening programs, the prognosis for PAH remains reserved.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pulmonary hypertension Source Type: research
ConclusionPatients who are at risk for SCA are patients who have had a cardiac arrest due to ventricular fibrillation (VF) or sustained ventricular tachycardia (SVT), those with familial or inherited condition with sudden cardiac arrest risk, myocardial infarction with an ejection fraction (EF) of less than or equal to 35%, dilated cardiomyopathy (including NICM), with an EF of less than or equal to 35%, ICD explanations, and other conditions with high risk of ventricular tachycardia (VT) or VF are candidates for the WCD.The sample of data was from 186 patients. However, more patients were likely candidates but may not hav...
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research
Ventricular assist devices (VADs) are currently standard therapy for patients with advanced heart failure that is refractory to medical therapy.1 VADs can be categorized as pulsatile flow VADs (PF-VADs) and continuous flow VADs (CF-VADs). Both PF-VADs and CF-VADs are similarly effective in providing hemodynamic benefit (augmenting cardiac output and end-organ perfusion, and reducing ventricular work), and improving the quality of life and functional capacity of patients.2,3 CF-VADs are preferred over the PF-VADs due to advantages including compact size, reliability, energy efficiency, ease of implantation, and operation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Pre-Clinical Science Source Type: research
More News: Cardiology | Heart | Heart Failure | Heart Transplant | Hospitals | Lung Transplant | Science | Transplant Surgery | Transplants